KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Accumulated Expenses (2016 - 2019)

Biomarin Pharmaceutical (BMRN) has disclosed Accumulated Expenses for 10 consecutive years, with $19.2 million as the latest value for Q1 2019.

  • For the quarter ending Q1 2019, Accumulated Expenses fell 74.9% year-over-year to $19.2 million, compared with a TTM value of $19.2 million through Mar 2019, down 74.9%, and an annual FY2018 reading of $20.0 million, up 6.15% over the prior year.
  • Accumulated Expenses was $19.2 million for Q1 2019 at Biomarin Pharmaceutical, down from $20.0 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $100.5 million in Q3 2017 and bottomed at $14.1 million in Q1 2017.
  • Average Accumulated Expenses over 5 years is $39.1 million, with a median of $32.5 million recorded in 2015.
  • The sharpest move saw Accumulated Expenses soared 660.33% in 2015, then crashed 80.84% in 2018.
  • Year by year, Accumulated Expenses stood at $95.3 million in 2015, then plummeted by 63.57% to $34.7 million in 2016, then plummeted by 45.82% to $18.8 million in 2017, then increased by 6.15% to $20.0 million in 2018, then fell by 3.77% to $19.2 million in 2019.
  • Business Quant data shows Accumulated Expenses for BMRN at $19.2 million in Q1 2019, $20.0 million in Q4 2018, and $19.3 million in Q3 2018.